This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
There are currently 23 open trials
Myeloma XII (ACCoRd)
Autologous stem cell transplant
The Myeloma XII trial is designed for myeloma patients at first relapse who have previously had a stem cell transplant and are now considering a second transplant.
The aim is to determine whether adding ixazomib (Ninlaro®) to conventional high-dose melphalan treatment can improve the depth of response of the second stem cell transplant, and whether ixazomib consolidation and maintenance treatment post-transplant can prolong the period of remission.
City Hospital, Nottingham;
Ninewells Hospital, Dundee;
Queen Elizabeth Hospital, Birmingham;
Southampton General Hospital, Southampton;
St Bartholomew's Hospital, London;
St James' Hospital, Leeds;
University College Hospital, London;
Norwich and Norfolk University Hospital, Norwich;
Stepping Hill Hospital, Stockport;
Lincoln County Hospital, Lincoln;
Pilgrim Hospital, Boston;
Grantham and District Hospital, Grantham;
Salisbury District Hospital, Salisbury;
Countess of Chester Hospital, Chester;
Queens Hospital, Burton upon Trent;
Blackpool Victoria Hospital, Blackpool;
Whiston Hospital, Prescot;
St Helens Hospital, Merseyside;
Barnsley Hospital, Barnsley;
Russells Hall Hospital, Dudley;
Pinderfields General Hospital, Wakefield;
Royal Stoke University Hospital, Stoke;
Dewsbury and District Hospital, Dewsbury;
Pontefract Hopsital, Pontefract;
Stafford County Hospital, Stafford
Who can enter the study?:
All patients receive 4 – 6 cycles of ixazomib in combination with thalidomide and dexamethasone (ITD) as re-induction treatment to reduce the extent of their myeloma. Ixazomib is given orally on days 1, 8 and 15 of a 28-day cycle, thalidomide on days 1 to 28 and dexamethasone on days 1, 8, 15 and 22.
Following re-induction treatment, patients are randomised to receive either conventional conditioning treatment with high-dose melphalan followed by autologous stem cell transplant or augmented conditioning with melphalan and ixazomib.
Assuming that the day of the stem cell transplant is day 0, ixazomib conditioning is given on day -4 and day -1 and melphalan conditioning on days -3 and -2.
Patients are assessed for response on day 100 and then randomised to receive either 2 cycles of ITD comsolidation followed by ixazomib maintenance treatment until signs relapse, or no further treatment.
Patients are required to attend outpatient clinics for regular checkups and blood tests.
(for Medical Professionals):
Myeloma XII is determining the role of ixazomib as an augmented conditioning treatment in the salvage transplant setting and as a post-transplant consolidation and maintenance strategy for myeloma patients at first relapse.
For more information, click here.